Qiagen to acquire diagnostics company STAT-Dx

Qiagen has agreed a deal to acquire STAT-Dx, a developer of next-generation multiplex diagnostics working on an innovative system for syndromic disease testing.

The company is creating a new platform for one-step, fully-integrated molecular analysis of common syndromes, using a novel system based on real-time polymerase chain reaction (PCR) technology and proven Qiagen chemistries.

Qiagen now plans to launch this system under the name QIAstat-Dx, with the goal of enabling scalable sample-to-insight processing of up to 48 molecular targets simultaneously, aiding the diagnosis of serious respiratory or gastrointestinal infections, as well as cancers. 

The system was unveiled in April 2017 and received CE-IVD approval in January 2018. The first two tests will be launched in Europe in the second half of 2018, followed by a US launch in 2019.

Peer Schatz, chief executive officer of Qiagen, said: "This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams."

This transaction is expected to close during the second quarter of this year.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.